FREQUENTLY ASKED QUESTIONS ABOUT DCIS OF THE BREAST.

Is Ductal Carcinoma in Situ (DCIS) cancer?
Cancer is a disease that starts as a growth in one place (for example, the breast or the colon or the lung) and spreads to other places. DCIS is a condition where abnormal cells appear in the milk ducts of the breast; “in situ” is Latin for “in place” so while the cells have some features of cancer, like the ability to grow abnormally, they don’t yet have the most important feature of cancer, which is the ability to spread to other parts of the body. In this sense, DCIS is not really cancer.

Does DCIS need treatment?
Strictly speaking, DCIS does not need treatment since abnormal cells inside the ducts are not causing any harm as long as they stay “in place” inside the duct. However, in some cases, if left alone long enough, the DCIS cells can learn to break through the duct wall and become “invasive”. The reason to treat DCIS is to prevent it from spreading beyond the duct.

What is the usual treatment for DCIS?
Because DCIS has a few different growth patterns, there can be different recommendations for treatment. Currently, DCIS is almost always removed surgically; many women are advised to have radiation after surgery; and if the DCIS cells have a protein that binds estrogen (called estrogen receptor or ER), women are advised to take tamoxifen or similar drugs to prevent new occurrences of DCIS or invasive cancer.

Why consider a DCIS clinical trial?
At the moment, women who want to have less-than-usual treatment for DCIS are encouraged to consider a clinical trial that tests a lesser approach to DCIS therapy, because we still have much to learn about how to best treat women with DCIS. We appreciate you considering this trial. Your care will not be affected by whether you choose to participate or not. Participation may not directly benefit you, but like the women before you who participated in trials and taught us how to treat breast cancer, you will help to increase our knowledge about how to give the women with DCIS the treatment they need (not too much, and not too little!)
If you would like to learn more about this study, please contact the study coordinators:

**Northwestern University**
Yanfei Xu  
yanfei-xu@northwestern.edu  
(312) 472-0585

**Duke University**
Clancy Leahy  
john.leahy@duke.edu  
(919) 681-2172

Kim Turnage  
kimberly.turnage@duke.edu  
(919) 681-5559

**Memorial Sloan Kettering Cancer Center**
Cristina Olcese  
olceseC@mskcc.org  
(646) 888-5229

**Cleveland Clinic**
Barbara Bevier  
bevierb@ccf.org  
(216) 445-9159

**Mayo Clinic**
Lisa Seymour  
Seymour.lisa@mayo.edu  
(507) 293-7698

**St Elizabeth Hospital**
Kimberly Schmidt  
Kimberly.Schmidt@stelizabeth.com  
(859) 301-9418

cancer.northwestern.edu/ncpc/NWU2015-06-04.cfm